In addition, since both aberrant TGFβ signaling and LyP-1 receptor expression are presented in several cancer types, mHAdLyp.sT-based immunotherapy approaches have the potential of targeting several other malignancies, too. This evidence concerns the gene TGFB1 and cancer.